Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2022-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Vivozon Healthcare' (now Vivozon Pharmaceutical) for the period ending September 30, 2022. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
[첨부추가]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from a South Korean company, specifically detailing the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정). This is a standard regulatory filing required by the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) for material corporate events. Since it details the issuance of new debt instruments (convertible bonds) and capital structure changes, it falls under the 'Capital/Financing Update' category.
2022-11-11 Korean
합병등종료보고서(합병)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the finalization of a merger between Vivozon Healthcare and Vivozon Pharmaceutical, including the timeline, shareholder voting results, creditor protection measures, and post-merger financial summaries. As this document pertains to the formal announcement and reporting of M&A activity completion, it falls under the M&A Activity category.
2022-11-01 Korean
본점소재지변경
Regulatory Filings Classification · 100% confidence The document is a short, formal announcement regarding a change in the company's registered office address (본점소재지변경). It provides specific details about the old and new addresses, the reason for the change (merger with Vivozon Pharmaceutical), and the effective date. Since this is a general regulatory announcement regarding corporate administrative changes that does not fit into specific categories like financial reports, dividends, or director dealings, it is classified as a general regulatory filing.
2022-11-01 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for Vivozon Healthcare. It details the resolutions passed, specifically the appointment of a director and changes to the company's business objectives. This falls under the category of Declaration of Voting Results, as it reports the outcome of shareholder voting at a general meeting.
2022-10-27 Korean
상호변경안내
Regulatory Filings Classification · 100% confidence The document is a formal announcement regarding a change in the company's name (Vivozon Healthcare to Vivozon Pharmaceutical). It details the change, the reason, and the date of the shareholder meeting where it was approved. Since this is a general regulatory announcement regarding corporate structure that does not fit into specific categories like M&A, Board changes, or Share issues, it falls under the general regulatory filing category.
2022-10-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.